All.Can Australia Limited leads collaborative research, policy advocacy, and the flagship Pan-Cancer Care Navigation Model to eliminate operational waste, reduce diagnostic delays, and achieve equitable cancer care across Australia.
Aligned with the Australian Cancer Plan, our model establishes standardized care navigation to reduce barriers for patients regardless of geographic location or tumor type.
All.Can Australia Limited is guided by a distinguished board of oncology leaders, academic researchers, and health policy experts.
University of Melbourne, Royal Melbourne Hospital & Peter MacCallum Cancer Centre. Internationally recognized surgical oncologist and health policy researcher.
Independent Board Member & former Chief Executive Officer of the Leukaemia Foundation. Leading healthcare advocate with decades of non-profit governance experience.
Monash University Head of Cancer Research. Renowned medical oncologist leading real-world cancer clinical registries and quality metrics.
Chief Executive Officer, Australian Healthcare & Hospitals Association (AHHA). Championing value-based healthcare reform across Australian hospitals.
Chief Executive Officer, The Society of Hospital Pharmacists of Australia (SHPA). Expert in health system navigation and oncology pharmacy services.
Rare Cancers Australia representative, advocating for equitable treatment pathways for patients diagnosed with rare and less common cancers.
Private Healthcare Australia representative, focusing on health economics and sustainable private/public healthcare integration.
Bristol-Myers Squibb representative, supporting innovative oncology access initiatives and multi-stakeholder partnerships.
Independent Director & MSD Market Access and Public Policy leader, championing evidence-based healthcare policy reform.
Collaborating across patient groups, research institutions, clinical societies, and health departments.
National alignment with the Australian Cancer Plan framework.
Australian Healthcare & Hospitals Association partner.
The Society of Hospital Pharmacists of Australia.
Advocating for rare and less common cancer patient pathways.
Clinical registry data & health outcome research partner.
Peter Mac Cancer Centre surgical & clinical expertise.
University of Melbourne health policy research group.
Healthcare Management Advisors research implementation.
Registered Australian Public Company Limited by Guarantee (ACNC Registered Charity, Chatswood NSW).
Incorporated on March 29, 2023, All.Can Australia Limited (ABN 45 659 843 400) operates as an independent Australian public company dedicated to sustainable healthcare policy.
We focus on creating actionable evidence and policy recommendations that address real-world bottlenecks in diagnostic pathways, treatment navigation, and post-treatment survivorship across all states and territories.
All.Can Australia Limited maintains full regulatory compliance under the Corporations Act 2001 and ACNC charity reporting standards.
Our strategic framework targets structural inefficiencies to deliver faster, more effective patient care.
Ensuring diagnostic pathways and multidisciplinary treatment teams prioritize patient quality of life, clear communication, and minimal waiting times.
Developing quantitative metrics to identify healthcare waste, measure diagnostic delays, and document real-world patient outcomes.
Collaborating with Australian federal and state healthcare authorities to implement sustainable funding models and clinical efficiency policies.
Redirecting financial and operational savings from administrative waste into advanced precision diagnostics and supportive patient navigation services.
Documented healthcare efficiency practices implemented across Australia and global health systems.
Standardized GP decision-support tools implemented across regional clinics to accelerate specialist oncology referrals for suspected solid tumors.
Deploying dedicated oncology nurse navigators to guide complex cases from initial diagnosis through post-treatment survivorship planning.
Integrating real-time digital symptom monitoring for chemotherapy patients to detect toxicities early and prevent emergency hospital readmissions.
Consolidating imaging, biopsy, and specialist consults into a single-day diagnostic hub for breast and lung cancer evaluations.
Open-access research papers providing evidence-based solutions for health policy makers and clinicians.
Comprehensive global research mapping key performance indicators to identify and eliminate non-value activities in cancer management.
View Report Summary →Actionable recommendations for healthcare systems to integrate efficiency metrics into national cancer control programs.
View Report Summary →Analysis of real-world patient experiences across 4,000+ respondents, documenting referral delays and information gaps.
View Report Summary →Strategic framework for clearing diagnostic backlogs, scaling digital health triage, and building resilient cancer care systems.
View Report Summary →Demonstrating how real-world health data and Patient-Reported Outcome Measures (PROMs) elevate care quality.
View Report Summary →Assess care coordination bottlenecks and generate tailored recommendations for patient pathways.
Your care pathway shows a baseline score. Streamlining primary care diagnostic referrals and deploying patient navigation support can significantly eliminate waste and reduce waiting anxiety.
Support Efficiency AdvocacyYour non-profit contribution directly funds open research, policy advocacy, and pan-cancer navigation initiatives.
